ANDREA LAUTER: Open Payments
NPI 1457490070 · NEW LONDON, CT. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,878 in 184 payments from 27 companies in 2025. Trend: 2023 $5,019 · 2024 $2,721 · 2025 $4,878
Food & beverage: $4,673Consulting: $150Education: $56
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 34 | $722 |
| Novartis Pharmaceuticals Corporation | 14 | $667 |
| EMD Serono, Inc. | 12 | $473 |
| UCB, Inc. | 12 | $431 |
| Biogen, Inc. | 10 | $300 |
| Celgene Corporation | 5 | $272 |
| Axsome Therapeutics, Inc. | 6 | $226 |
| AstraZeneca Pharmaceuticals LP | 6 | $198 |
| Vanda Pharmaceuticals Inc. | 8 | $194 |
| PFIZER INC. | 9 | $180 |
Products named: KESIMPTA, QULIPTA, TYSABRI, Fintepla, ZEPOSIA, Symbravo, UBRELVY, WAINUA.
Industry payments across CT — which companies pay providers there.
